<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060044</url>
  </required_header>
  <id_info>
    <org_study_id>3106010</org_study_id>
    <nct_id>NCT03060044</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</brief_title>
  <official_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µg/Inhalation: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus
      50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in
      healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of plasma salmeterol and fluticasone propionate</measure>
    <time_frame>0 hour to 34 hours after study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of plasma salmeterol and fluticasone propionate</measure>
    <time_frame>0 hour to 34 hours after study treatment administration</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Salmeterol/fluticasone Easyhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler with charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Seretide Diskus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus with charcoal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Seretide Diskus with concomitant charcoal administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/fluticasone Easyhaler</intervention_name>
    <arm_group_label>Salmeterol/fluticasone Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/fluticasone Easyhaler with charcoal</intervention_name>
    <arm_group_label>Salmeterol/fluticasone Easyhaler with charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus</intervention_name>
    <arm_group_label>Seretide Diskus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus with charcoal</intervention_name>
    <arm_group_label>Seretide Diskus with charcoal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent obtained

          -  good general health ascertained by detailed medical history, and laboratory and
             physical examinations

        Exclusion Criteria:

          -  evidence of a clinically significant cardiovascular, renal, hepatic, hematological,
             GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease within the
             previous 2 years

          -  any condition requiring concomitant treatment (including vitamins and herbal
             products)or likely to need any concomitant treatment during the study. as an exception
             paracetamol and ibuprofen for occasional pain are allowed

          -  known hypersensitivity to the active substance(s) or the excipient (lactose, which
             contains small amounts of milk protein) of the drug

          -  pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iissa Kivistö</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Study director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orion Pharma pharmacology Unit</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

